Medicare Enrolled
Dr. Muralidhar Beeram, M.D.
Medical Oncology · San Antonio, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Beeram from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Beeram?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Beeram
Dr. Muralidhar Beeram is a medical oncology specialist in San Antonio, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Beeram performed 11,750 Medicare services across 1,941 unique beneficiaries.
Between the years covered by Open Payments, Dr. Beeram received a total of $107,662 from 76 pharmaceutical and/or device companies across 690 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Beeram is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 40% volume in TX
$107,662 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,750
Medicare services
Top 40% in TX for medical oncology
1,941
Unique beneficiaries
$24
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~588 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 3,900 | $18 | $71 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,434 | $0 | $0 |
| Injection, potassium chloride, per 2 meq | 940 | $0 | $0 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
701 | $10 | $32 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
656 | $8 | $23 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
462 | $1 | $2 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
406 | $22 | $86 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
380 | $8 | $16 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
375 | $94 | $373 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
317 | $100 | $377 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
291 | $133 | $523 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
145 | $6 | $69 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
140 | $12 | $58 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
129 | $7 | $20 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
122 | $50 | $205 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 109 | $358 | $1,365 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
104 | $6 | $18 |
| Iron level test | 96 | $6 | $19 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
96 | $9 | $26 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
96 | $11 | $47 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
95 | $1 | $3 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
93 | $13 | $41 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
91 | $48 | $185 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
82 | $16 | $60 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
69 | $22 | $90 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
64 | $10 | $42 |
| New patient office visit, complex (60-74 min) | 47 | $172 | $641 |
| Vitamin B-12 level test A blood test that measures the amount of vitamin B-12 in your body. |
46 | $15 | $45 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
44 | $6 | $19 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
43 | $2 | $19 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
36 | $62 | $232 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
35 | $25 | $137 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 34 | $20 | $62 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
33 | $65 | $271 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
20 | $9 | $28 |
| Uric acid level test A blood test that measures the level of uric acid in your body. Uric acid is a waste product formed when the body breaks down purines. |
19 | $4 | $14 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.3% high complexity
62.9% medium
27.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$107,662
Total received (2018-2024)
Avg $15,380/year across 7 years
Top 13% in TX for medical oncology
76
Companies
690
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$96,180 (89.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,355 (9.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,127 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$9,480
2023
$3,205
2022
$6,738
2021
$2,668
2020
$5,028
2019
$59,392
2018
$21,150
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$52,227
Merck Sharp & Dohme Corporation
$27,400
Merck Sharp & Dohme LLC
$11,751
E.R. Squibb & Sons, L.L.C.
$6,263
Novartis Pharmaceuticals Corporation
$1,441
AstraZeneca Pharmaceuticals LP
$993
Eli Lilly and Company
$800
Janssen Biotech, Inc.
$757
Daiichi Sankyo Inc.
$331
Amgen Inc.
$275
Celgene Corporation
$270
PFIZER INC.
$264
Takeda Pharmaceuticals U.S.A., Inc.
$263
Eisai Inc.
$254
Lilly USA, LLC
$234
Incyte Corporation
$229
GENZYME CORPORATION
$218
Janssen Pharmaceuticals, Inc
$183
Gilead Sciences, Inc.
$174
AbbVie, Inc.
$166
Astellas Pharma US Inc
$163
Karyopharm Therapeutics Inc.
$159
Bayer Healthcare Pharmaceuticals Inc.
$153
Regeneron Healthcare Solutions, Inc.
$141
Puma Biotechnology, Inc.
$138
Genmab U.S., Inc.
$129
Ipsen Biopharmaceuticals, Inc
$119
Myriad Genetic Laboratories, Inc.
$115
GlaxoSmithKline, LLC.
$97
Bayer HealthCare Pharmaceuticals Inc.
$91
EMD Serono, Inc.
$89
PharmaEssentia USA Corporation
$88
AVEO Pharmaceuticals, Inc.
$83
Boehringer Ingelheim Pharmaceuticals, Inc.
$82
ADC Therapeutics America, Inc.
$68
Stemline Therapeutics Inc.
$67
Taiho Oncology, Inc.
$64
PUMA BIOTECHNOLOGY, INC.
$62
Kyowa Kirin, Inc.
$61
Alexion Pharmaceuticals, Inc.
$58
Immunocore Limited
$57
Pharmacyclics LLC, An AbbVie Company
$56
MorphoSys, US Inc.
$56
Kite Pharma, Inc.
$52
Seagen Inc.
$52
Seattle Genetics, Inc.
$49
Teva Pharmaceuticals USA, Inc.
$48
ABBVIE INC.
$45
Medtronic USA, Inc.
$45
TAIHO ONCOLOGY, INC.
$45
SOBI, INC
$44
Agios Pharmaceuticals, Inc.
$38
Mirati Therapeutics, Inc.
$37
EISAI INC.
$34
SERVIER PHARMACEUTICALS LLC
$33
Deciphera Pharmaceuticals Inc.
$32
JAZZ PHARMACEUTICALS INC.
$32
Blueprint Medicines Corporation
$32
Sobi, Inc
$31
Exelixis Inc.
$28
Foundation Medicine, Inc.
$26
Rigel Pharmaceuticals, Inc.
$24
AMAG Pharmaceuticals, Inc.
$23
Sirtex Medical Inc
$21
ARRAY BIOPHARMA INC
$21
RECORDATI_RARE_DISEASES_INC.
$20
SpringWorks Therapeutics, Inc.
$20
AbbVie Inc.
$19
Fennec Pharmaceuticals, Inc.
$18
CTI BioPharma Corp.
$18
Pharmacosmos Therapeutics Inc.
$17
Heron Therapeutics, Inc.
$16
Aveo Pharmaceuticals, Inc.
$15
Jazz Pharmaceuticals Inc.
$14
Helsinn Therapeutics (U.S.), Inc.
$12
Array BioPharma Inc.
$11
Top 3 companies account for 84.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AUGTYRO · AYVAKIT · Abraxane · BALVERSA · BAVENCIO · BENDEKA · BESREMI · BLENREP · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CINVANTI · CYRAMZA · Columvi · Creon · DARZALEX · DOPTELET · Doptelet · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · Enhertu · Epkinly · Erleada · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · Gazyva · Halaven · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · Imbruvica · JADENU · JAKAFI · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · OSTEOCOOL RF ABLATION · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · PRECISETUMOR · PROMACTA · PYRUKYND · Padcev · Pedmark · Perjeta · Phesgo · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYLVANT · SYNCHROMED · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · VYXEOS · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Yescarta · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (89%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $916 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
37
Per 100K population
1.8
County median income
$70,571
Nearest hospital
UNIVERSITY HEALTH SYSTEM
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Beeram is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 13% of TX peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Beeram experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Beeram performed 3,900 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Beeram receive payments from pharmaceutical companies?
Yes. Dr. Beeram received a total of $107,662 from 76 companies across 690 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Beeram's costs compare to other medical oncologists in San Antonio?
Dr. Beeram's average Medicare payment per service is $24. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Beeram) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in San Antonio
Browse medical oncologists in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology